<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344758</url>
  </required_header>
  <id_info>
    <org_study_id>CELIFLUID1</org_study_id>
    <nct_id>NCT02344758</nct_id>
  </id_info>
  <brief_title>Gluten-free Diet Monitoring in Urine</brief_title>
  <official_title>Non-invasive Gluten-free Diet Adherence Monitoring in Celiac Patients: Detection of Gluten Immunogenic Peptides in Urine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Seville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Hispalense de Pediatría</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Seville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develope a novel method to determine gluten intake and to
      check gluten-free diet adherence in celiac patients by detection of gluten immunogenic
      peptides in urine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, the mainstay of the management of CD is a strict life-long adherence to gluten-free
      diet (GFD). Follow-up monitoring of the improvement of patients on GFD is essential to assess
      symptomatic recovery and to monitor complications, as well as to assist patients with dietary
      compliance. However, practical methods to monitor diet compliance and to detect the origin of
      an outbreak of celiac clinical symptoms are not available.

      In this study, we have overcome these challenges and shown the feasibility of measuring
      gluten immunogenic peptides (GIP) in urine samples in healthy and celiac individuals by solid
      phase extraction and estimating the peptide concentrations with a reader of anti-GIP moAb
      immunochromatographic strips (IC-strips).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
  </study_design_info>
  <primary_outcome>
    <measure>Usual gluten-containing diet for healthy individuals</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usual gluten-free diet for celiac patients (home diet not modified for this trial)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Gluten-challenge in healthy individuals on GFD with 10 to 50 mg gluten</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Celiac adult</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient &gt;16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for &gt;2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac child</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient &lt;16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for &gt;2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy adult</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy individual &gt; 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy child</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy individual &lt; 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive lateral flow test for monitoring gluten intake</intervention_name>
    <arm_group_label>Celiac adult</arm_group_label>
    <arm_group_label>Celiac child</arm_group_label>
    <arm_group_label>Healthy adult</arm_group_label>
    <arm_group_label>Healthy child</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>gluten-free diet (GFD)</intervention_name>
    <arm_group_label>Celiac adult</arm_group_label>
    <arm_group_label>Celiac child</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>gluten-containing diet</intervention_name>
    <arm_group_label>Healthy adult</arm_group_label>
    <arm_group_label>Healthy child</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Celiac patient: childs (&lt; 16 years) and adults (&gt; 16 years)

          -  written informed consent

        Exclusion Criteria:

          -  presence of family history of CD

          -  digestive disease symptoms

          -  known medical disease

          -  use of prescription medications and use of antibiotics and probiotics in the previous
             2 months to the inclusion in the study

          -  participation in any other studies involving investigational concomitantly or within
             two weeks prior to entry into the study and during the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mª de Lourdes Moreno Amador, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Microbiology and Parasitology, University of Sevilla, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ángel Cebolla Ramírez, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Biomedal S.L.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ángeles Pizarro Moreno, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad Clínica de Aparato Digestivo, Hospital Universitario Virgen del Rocío, Sevilla, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alba Muñoz Suano, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Biomedal, S.L., Sevilla, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Comino Montilla, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Microbiology and Parasitology, University of Sevilla, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Rodríguez Herrera, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad de Gastroenterología y Nutrición, Instituto Hispalense de Pediatría. Sevilla, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco León, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Celimmune, Bethesda, MD, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolina Carrillo Carrión</last_name>
    <role>Study Chair</role>
    <affiliation>Biomedal, S.L., Sevilla, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolina Sousa Martín, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Microbiology and Parasitology, University of Sevilla, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville</name>
      <address>
        <city>Seville</city>
        <zip>41012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Morón B, Bethune MT, Comino I, Manyani H, Ferragud M, López MC, Cebolla A, Khosla C, Sousa C. Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide. PLoS One. 2008 May 28;3(5):e2294. doi: 10.1371/journal.pone.0002294.</citation>
    <PMID>18509534</PMID>
  </reference>
  <reference>
    <citation>Morón B, Cebolla A, Manyani H, Alvarez-Maqueda M, Megías M, Thomas Mdel C, López MC, Sousa C. Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide. Am J Clin Nutr. 2008 Feb;87(2):405-14.</citation>
    <PMID>18258632</PMID>
  </reference>
  <reference>
    <citation>Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol. 2002 Oct;283(4):G996-G1003.</citation>
    <PMID>12223360</PMID>
  </reference>
  <reference>
    <citation>Shan L, Molberg Ø, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C. Structural basis for gluten intolerance in celiac sprue. Science. 2002 Sep 27;297(5590):2275-9.</citation>
    <PMID>12351792</PMID>
  </reference>
  <reference>
    <citation>Comino I, Real A, Vivas S, Síglez MÁ, Caminero A, Nistal E, Casqueiro J, Rodríguez-Herrera A, Cebolla A, Sousa C. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. Am J Clin Nutr. 2012 Mar;95(3):670-7. doi: 10.3945/ajcn.111.026708. Epub 2012 Jan 18.</citation>
    <PMID>22258271</PMID>
  </reference>
  <reference>
    <citation>Comino I, Real A, Moreno Mde L, Montes R, Cebolla A, Sousa C. Immunological determination of gliadin 33-mer equivalent peptides in beers as a specific and practical analytical method to assess safety for celiac patients. J Sci Food Agric. 2013 Mar 15;93(4):933-43. doi: 10.1002/jsfa.5830. Epub 2012 Aug 6.</citation>
    <PMID>22886585</PMID>
  </reference>
  <reference>
    <citation>Real A, Comino I, Moreno Mde L, López-Casado MÁ, Lorite P, Torres MI, Cebolla Á, Sousa C. Identification and in vitro reactivity of celiac immunoactive peptides in an apparent gluten-free beer. PLoS One. 2014 Jun 25;9(6):e100917. doi: 10.1371/journal.pone.0100917. eCollection 2014.</citation>
    <PMID>24963630</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Seville</investigator_affiliation>
    <investigator_full_name>Carolina Sousa Martin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

